Suchergebnisse - "Besemer, Britta"

PubPharm (53)

1

Predictors of early morbidity and mortality in newly diagnosed multiple myeloma : data from five randomized, controlled, phase III trials in 3700 patients

enthalten in: Leukemia | 2024

von Mai, E. | Hielscher, T. | Bertsch, U. | +26

2

Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma : Results From the Phase II MajesTEC-1 Study

enthalten in: Clinical lymphoma, myeloma & leukemia | 2024

von Martin, T. | Moreau, P. | Usmani, S. | +20

3

Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

enthalten in: Advances in therapy | 2024

von Moreau, P. | Mateos, M. | Gonzalez Garcia, M. | +26

4

Sequence diversity of kappa light chains from patients with AL amyloidosis and multiple myeloma

enthalten in: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis | 2024

von Schreiner, S. | Berghaus, N. | Poos, A. | +10

5

Real-world analysis of teclistamab in 123 RRMM patients from Germany

enthalten in: Leukemia | 20 January 2024

von Riedhammer, C. | Bassermann, F. | Besemer, B. | +23

6

Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6) : results from a randomised, phase 3 trial

enthalten in: The lancet / Haematology | February 2024

von Mai, E. | Goldschmidt, H. | Miah, K. | +32

7

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Leypoldt, L. | Tichy, D. | Besemer, B. | +24

8

Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6) : results from a randomised, phase 3 trial

enthalten in: The Lancet. Haematology | 2024

von Mai, E. | Goldschmid, H. | Miah, K. | +74

ErratumIn: Lancet Haematol. 2024 Feb 7;:. - PMID 38340740

9

Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial

enthalten in: Hematology (Amsterdam, Netherlands) | 2024

von Salwender, H. | Weinhold, N. | Benner, A. | +23

10

Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

enthalten in: Advances in therapy | 2023

von Moreau, P. | Mateos, M. | Gonzalez Garcia, M. | +26

1
2
3
4
5
6
Nächster »
[6]